Giralt, Sergio

Publications

Sort by

Co-Author Network

selected publications

Prognostic Factors for Postrelapse Survival after ex Vivo CD34⁺-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone marrow transplantation. 2020 Letter GET IT
Times cited: 4
Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 Academic Article GET IT
Times cited: 41
Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 16
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood. 2020 Academic Article GET IT
Times cited: 103
Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. Leukemia. 2020 Academic Article GET IT
Times cited: 10
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 9
Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series. Bone marrow transplantation. 2020 Article GET IT
Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 38
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood advances. 2020 Academic Article GET IT
Times cited: 112
A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 46
Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 15
A key step towards setting a benchmark for tackling transplant-associated thrombotic microangiopathy. British journal of haematology. 2020 Article GET IT
Times cited: 1
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 176
A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study. Leukemia & lymphoma. 2020 Article GET IT
Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. Bone marrow transplantation. 2020 Letter GET IT
Times cited: 2
Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. Blood advances. 2020 Academic Article GET IT
Times cited: 35
Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 4
Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34⁺ selected graft. Bone marrow transplantation. 2019 Letter GET IT
Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. Transplant infectious disease : an official journal of the Transplantation Society. 2019 Academic Article GET IT
Times cited: 68
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 21
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34⁺-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 9
Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone marrow transplantation. 2019 Academic Article GET IT
Times cited: 39
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 59
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 12
Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. Expert review of hematology. 2019 Information Resource GET IT
Times cited: 1
Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. Blood advances. 2019 Academic Article GET IT
Times cited: 71
Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. Expert review of hematology. 2019 Information Resource GET IT
Times cited: 2
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34⁺ Selected Allogeneic Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 15
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). The Lancet. Haematology. 2019 Academic Article GET IT
Times cited: 201
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 196
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults. Blood advances. 2019 Academic Article GET IT
Times cited: 26
Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 8
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 47
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. Blood advances. 2018 Academic Article GET IT
Times cited: 42
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. British journal of haematology. 2018 Academic Article GET IT
Times cited: 52
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica. 2018 Academic Article GET IT
Times cited: 13
Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 7
Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. Bone marrow transplantation. 2018 Information Resource GET IT
Times cited: 2
Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. Journal of hematology & oncology. 2018 Academic Article GET IT
Times cited: 16
Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Science translational medicine. 2018 Academic Article GET IT
Times cited: 257
Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 17
End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. Bone marrow transplantation. 2018 Academic Article GET IT
Times cited: 9
Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 14
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 130
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 9
Cytomegalovirus resistance in CD34⁺ -selected hematopoietic cell transplant recipients. Transplant infectious disease : an official journal of the Transplantation Society. 2018 Academic Article GET IT
Times cited: 12
Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. Current hematologic malignancy reports. 2018 Information Resource GET IT
Times cited: 15
Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience. Bone marrow transplantation. 2018 Article GET IT
Times cited: 20
Severe pembrolizumab-associated neutropenia after CD34⁺ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. Bone marrow transplantation. 2018 Article GET IT
Times cited: 6
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Information Resource GET IT
Times cited: 63
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 16
Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma. Bone marrow transplantation. 2018 Article GET IT
Times cited: 1
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone marrow transplantation. 2018 Academic Article GET IT
Times cited: 94
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34⁺ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 19
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 40
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia & lymphoma. 2018 Letter GET IT
Times cited: 14
CD34⁺ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome . Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 16
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 33
Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 14
Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2017 Academic Article GET IT
Times cited: 1
FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. JAMA. 2017 Article GET IT
Times cited: 102
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2017 Information Resource GET IT
Times cited: 228
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. Leukemia & lymphoma. 2017 Information Resource GET IT
Times cited: 46
Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Information Resource GET IT
Times cited: 19
Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis. Bone marrow transplantation. 2017 Academic Article GET IT
Times cited: 8
Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation. Bone marrow transplantation. 2017 Editorial Article GET IT
Times cited: 4
Impact of Toxicity on Survival for Older Adult Patients after CD34⁺ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 13
Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 Academic Article GET IT
Times cited: 24
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34⁺-Selected Allogeneic Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 11
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. The Lancet. Haematology. 2017 Academic Article GET IT
Times cited: 136
T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 8
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34⁺-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 9
Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 12
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 Academic Article GET IT
Times cited: 218
Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34⁺ Selected Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 32
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia & lymphoma. 2017 Article GET IT
Times cited: 1
Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. The Journal of infectious diseases. 2017 Academic Article GET IT
Times cited: 68
Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 22
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 245
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 79
Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 33
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 499
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017 Information Resource GET IT
Times cited: 279
Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants. Bone marrow transplantation. 2017 Academic Article GET IT
Times cited: 12
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 52
Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 50
Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2017 Information Resource GET IT
Times cited: 28
Ex Vivo CD34⁺-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016 Academic Article GET IT
Times cited: 33
Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia & lymphoma. 2016 Article GET IT
Times cited: 7
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34⁺ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016 Academic Article GET IT
Times cited: 22
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 12
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016 Academic Article GET IT
Times cited: 18
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2016 Academic Article GET IT
Times cited: 83
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clinical biochemistry. 2016 Academic Article GET IT
Times cited: 56
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Where Are We Going With This?. Journal of oncology practice. 2016 Article GET IT
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia. 2016 Academic Article GET IT
Times cited: 50
Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation. American journal of respiratory and critical care medicine. 2016 Academic Article GET IT
Times cited: 91
A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions. Bone marrow transplantation. 2016 Information Resource GET IT
Times cited: 65
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. British journal of haematology. 2016 Article GET IT
Times cited: 2
Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Academic Article GET IT
Times cited: 22
Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016 Academic Article GET IT
Times cited: 10
Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016 Academic Article GET IT
Times cited: 28
Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood reviews. 2016 Information Resource GET IT
Times cited: 107
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016 Article GET IT
Times cited: 14
MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients. Bone marrow transplantation. 2016 Article GET IT
Times cited: 16
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months. British journal of haematology. 2016 Academic Article GET IT
Times cited: 13
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Academic Article GET IT
Times cited: 249
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 5
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone marrow transplantation. 2016 Academic Article GET IT
Times cited: 46
Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Academic Article GET IT
Times cited: 36
Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Critical reviews in oncology/hematology. 2015 Information Resource GET IT
Times cited: 43
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 132
Busulfan-based conditioning regimens: not all partners are equal. The Lancet. Oncology. 2015 Article GET IT
Times cited: 3
Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Information Resource GET IT
Times cited: 117
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer immunology research. 2015 Academic Article GET IT
Times cited: 155
Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation. The oncologist. 2015 Academic Article GET IT
Times cited: 40
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 22
Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 26
Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 31
Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Information Resource GET IT
Times cited: 34
Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 13
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 37
Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 8
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic proceedings. 2015 Article GET IT
Times cited: 129
CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 44
Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. Bone marrow transplantation. 2015 Academic Article GET IT
Times cited: 16
Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 8
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 551
Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 32
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?. Bone marrow transplantation. 2015 Information Resource GET IT
Times cited: 11
Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone marrow transplantation. 2015 Academic Article GET IT
Times cited: 32
Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. Bone marrow transplantation. 2015 Academic Article GET IT
Times cited: 15
Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 21
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2014 Academic Article GET IT
Times cited: 91
The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies. Leukemia & lymphoma. 2014 Information Resource GET IT
Times cited: 5
Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 24
Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. Blood. 2014 Academic Article GET IT
Times cited: 71
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 50
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 18
Treatment of transplant-eligible patients with multiple myeloma in 2014. Hematology/oncology clinics of North America. 2014 Information Resource GET IT
Times cited: 4
Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leukemia & lymphoma. 2014 Article GET IT
Times cited: 4
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2014 Academic Article GET IT
Times cited: 120
Donor-recipient allele-level HLA matching of unrelated cord blood units reveals high degrees of mismatch and alters graft selection. Bone marrow transplantation. 2014 Academic Article GET IT
Times cited: 14
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014 Academic Article GET IT
Times cited: 70
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014 Academic Article GET IT
Times cited: 671
Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study. The Journal of infection. 2014 Academic Article GET IT
Times cited: 29
The future of autologous stem cell transplantation in myeloma. Blood. 2014 Information Resource GET IT
Times cited: 37
Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone marrow transplantation. 2014 Academic Article GET IT
Times cited: 14
Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. Journal of geriatric oncology. 2014 Academic Article GET IT
Times cited: 57
Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T Cell-depleted peripheral blood and cord blood stem cell transplantations. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 21
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 83
A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 8
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. American journal of hematology. 2014 Academic Article GET IT
Times cited: 54
Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 62
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 2060
Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 42
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Expert review of hematology. 2014 Information Resource GET IT
Times cited: 12
Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 20
"No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 15
BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation. 2013 GET IT
Times cited: 17
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 35
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Conference Paper GET IT
Times cited: 11
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 22
Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 26
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance. Leukemia. 2013 Article GET IT
Times cited: 11
Authors' reply to Tendas et al. Journal of pain and symptom management. 2013 Article GET IT
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 81
A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 56
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 58
Assessing response of therapy for acute and chronic graft-versus-host disease. Expert review of hematology. 2013 Information Resource GET IT
Times cited: 6
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. American journal of hematology. 2013 Academic Article GET IT
Times cited: 12
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone marrow transplantation. 2013 Academic Article GET IT
Times cited: 27
Salvage second hematopoietic cell transplantation in myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 97
Drug safety evaluation of defibrotide. Expert opinion on drug safety. 2012 Information Resource GET IT
Times cited: 47
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012 Academic Article GET IT
Times cited: 12
Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care. Current opinion in oncology. 2012 Information Resource GET IT
Times cited: 13
Light-chain amyloidosis: SCT, novel agents and beyond. Bone marrow transplantation. 2012 Information Resource GET IT
Times cited: 9
Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012 Academic Article GET IT
Times cited: 54
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2012 Academic Article GET IT
Times cited: 74
Cancer-testis antigen expression and immunogenicity in AL amyloidosis. Blood cancer journal. 2012 Academic Article GET IT
Times cited: 9
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012 Academic Article GET IT
Times cited: 37
Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. Bone marrow transplantation. 2012 Academic Article GET IT
Times cited: 43
Graft-versus-host disease: have we solved the problem?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Editorial Article GET IT
Times cited: 3
Late effects and healthcare needs of survivors of allogeneic stem cell transplantation: a qualitative study. BMJ supportive & palliative care. 2012 Academic Article GET IT
Times cited: 12
Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nature reviews. Clinical oncology. 2012 Information Resource GET IT
Times cited: 65
Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation. Journal of pain and symptom management. 2012 Academic Article GET IT
Times cited: 85
Lenalidomide after stem-cell transplantation for multiple myeloma. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 985
Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. The journal of pain. 2012 Academic Article GET IT
Times cited: 37
Stem cell transplantation for multiple myeloma: current and future status. Hematology (Amsterdam, Netherlands). 2012 Academic Article GET IT
Times cited: 12
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012 Academic Article GET IT
Times cited: 43
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 22
Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 35
The use of back-up units to enhance the safety of unrelated donor cord blood transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012 Academic Article GET IT
Times cited: 14
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. American journal of hematology. 2012 Academic Article GET IT
Times cited: 23
Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leukemia & lymphoma. 2012 Article GET IT
Times cited: 21
Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation. Bone marrow transplantation. 2011 Academic Article GET IT
Times cited: 11
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leukemia & lymphoma. 2011 Academic Article GET IT
Times cited: 21
Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2011 Academic Article GET IT
Times cited: 67
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone marrow transplantation. 2011 Academic Article GET IT
Times cited: 78
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. The Lancet. Oncology. 2011 Academic Article GET IT
Times cited: 253
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2011 Academic Article GET IT
Times cited: 38
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leukemia & lymphoma. 2011 Academic Article GET IT
Times cited: 62
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011 Academic Article GET IT
Times cited: 64
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011 Academic Article GET IT
Times cited: 80
ATG and RIC: not such a good match?. Blood. 2011 Article GET IT
Times cited: 1
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer research. 2011 Academic Article GET IT
Times cited: 13
Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011 Academic Article GET IT
Times cited: 17
Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion. 2011 Academic Article GET IT
Times cited: 14
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone marrow transplantation. 2011 Academic Article GET IT
Times cited: 239
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone marrow transplantation. 2011 Academic Article GET IT
Times cited: 21
Prognostic value of response after upfront therapy for acute GVHD. Bone marrow transplantation. 2011 Academic Article GET IT
Times cited: 36
Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011 Academic Article GET IT
Times cited: 90
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011 Academic Article GET IT
Times cited: 88
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 Conference Paper GET IT
Times cited: 328
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011 Academic Article GET IT
Times cited: 66
Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Information Resource GET IT
Times cited: 28
TMLI: a better TBI or more of the same?. Blood. 2011 Article GET IT
Stem cell transplantation for multiple myeloma: current and future status. Hematology. American Society of Hematology. Education Program. 2011 Information Resource GET IT
Times cited: 22
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2010 Academic Article GET IT
Times cited: 69
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood. 2010 Academic Article GET IT
Times cited: 109
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 25
Unrelated donor transplantation for acute myelogenous leukemia in first remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Academic Article GET IT
Times cited: 6
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Information Resource GET IT
Times cited: 294
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 32
200 mg/m(2) melphalan--the gold standard for multiple myeloma. Nature reviews. Clinical oncology. 2010 Article GET IT
Times cited: 10
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leukemia & lymphoma. 2010 Academic Article GET IT
Times cited: 5
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010 Academic Article GET IT
Times cited: 26
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010 Academic Article GET IT
Times cited: 390
The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. American journal of hematology. 2010 Academic Article GET IT
Times cited: 5
Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone marrow transplantation. 2010 Academic Article GET IT
Times cited: 22
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Academic Article GET IT
Times cited: 67
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Information Resource GET IT
Times cited: 45
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Information Resource GET IT
Times cited: 90
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010 Academic Article GET IT
Times cited: 134
A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. Journal of blood medicine. 2010 Academic Article GET IT
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Information Resource GET IT
Times cited: 161
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology (Amsterdam, Netherlands). 2010 Academic Article GET IT
Times cited: 14
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 416
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Editorial Article GET IT
Times cited: 21
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Academic Article GET IT
Times cited: 30
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Academic Article GET IT
Times cited: 47
Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Academic Article GET IT
Times cited: 18
Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. International journal of hematology. 2009 Academic Article GET IT
Times cited: 5
Outcome of transplantation for myelofibrosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 222
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009 Academic Article GET IT
Times cited: 215
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 101
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Information Resource GET IT
Times cited: 472
Defining the intensity of conditioning regimens: working definitions. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 1393
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 60
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone marrow transplantation. 2009 Academic Article GET IT
Times cited: 50
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood. 2009 Academic Article GET IT
Times cited: 76
Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 35
Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?. Clinical lymphoma & myeloma. 2009 Information Resource GET IT
Times cited: 5
Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 4
CR represents an early index of potential long survival in multiple myeloma. Bone marrow transplantation. 2009 Academic Article GET IT
Times cited: 48
Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 68
Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. Oncology. 2009 Academic Article GET IT
Times cited: 1
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. Journal of the National Cancer Institute. 2009 Article GET IT
Times cited: 9
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. American journal of hematology. 2009 Academic Article GET IT
Times cited: 92
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 52
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 Academic Article GET IT
Times cited: 184
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 148
A randomized control trial of a supervised versus a self-directed exercise program for allogeneic stem cell transplant patients. Psycho-oncology. 2009 Academic Article GET IT
Times cited: 55
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Academic Article GET IT
Times cited: 176
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone marrow transplantation. 2009 Academic Article GET IT
Times cited: 68
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009 Academic Article GET IT
Times cited: 42
Advances in stem cell transplantation: making it better and safer. Clinical lymphoma & myeloma. 2009 Information Resource GET IT
Times cited: 3
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clinical lymphoma & myeloma. 2009 Information Resource GET IT
Times cited: 13
Principles and overview of allogeneic hematopoietic stem cell transplantation. Cancer treatment and research. 2009 Information Resource GET IT
Times cited: 41
The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. The Internet journal of hematology. 2009 Academic Article GET IT
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 91
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 41
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone marrow transplantation. 2008 Academic Article GET IT
Times cited: 6
Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008 Academic Article GET IT
Times cited: 67
Comparison of twin and autologous transplants for multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 26
Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 67
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008 Academic Article GET IT
Times cited: 117
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. British journal of haematology. 2008 Academic Article GET IT
Times cited: 23
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 148
Is reduced-intensity conditioning the standard of care in the transplant setting?. Clinical advances in hematology & oncology : H&O. 2008 Academic Article GET IT
Times cited: 1
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Academic Article GET IT
Times cited: 272
Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer. 2008 Academic Article GET IT
Times cited: 27
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 40
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Academic Article GET IT
Times cited: 124
Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 66
Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone marrow transplantation. 2007 Academic Article GET IT
Times cited: 46
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2007 Academic Article GET IT
Times cited: 41
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clinical advances in hematology & oncology : H&O. 2007 Conference Paper GET IT
Times cited: 5
Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007 Academic Article GET IT
Times cited: 124
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007 Academic Article GET IT
Times cited: 296
Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia. 2007 Academic Article GET IT
Times cited: 22
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007 Academic Article GET IT
Times cited: 47
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2007 Academic Article GET IT
Times cited: 32
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Academic Article GET IT
Times cited: 50
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia. 2007 Article GET IT
Times cited: 46
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone marrow transplantation. 2007 Academic Article GET IT
Times cited: 39
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology (Amsterdam, Netherlands). 2007 Academic Article GET IT
Times cited: 96
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone marrow transplantation. 2007 Academic Article GET IT
Times cited: 95
Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2007 Academic Article GET IT
Times cited: 61
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. British journal of haematology. 2007 Academic Article GET IT
Times cited: 80
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. British journal of haematology. 2007 Academic Article GET IT
Times cited: 64
Symptom burden in patients undergoing autologous stem-cell transplantation. Bone marrow transplantation. 2007 Academic Article GET IT
Times cited: 82
Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007 Academic Article GET IT
Times cited: 73
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2007 Academic Article GET IT
Times cited: 25
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2007 Academic Article GET IT
Times cited: 108
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2007 Academic Article GET IT
Times cited: 42
Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone marrow transplantation. 2007 Academic Article GET IT
Times cited: 38
Quantitative sensory findings in patients with bortezomib-induced pain. The journal of pain. 2006 Academic Article GET IT
Times cited: 126
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2006 Academic Article GET IT
Times cited: 203
Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion. 2006 Academic Article GET IT
Times cited: 63
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone marrow transplantation. 2006 Academic Article GET IT
Times cited: 33
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2006 Academic Article GET IT
Times cited: 52
Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone marrow transplantation. 2006 Academic Article GET IT
Times cited: 40
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leukemia & lymphoma. 2006 Academic Article GET IT
Times cited: 12
Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leukemia & lymphoma. 2006 Academic Article GET IT
Times cited: 6
Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone marrow transplantation. 2006 Academic Article GET IT
Times cited: 33
Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. British journal of haematology. 2006 Academic Article GET IT
Times cited: 42
High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone marrow transplantation. 2006 Academic Article GET IT
Times cited: 4
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Academic Article GET IT
Times cited: 78
Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006 Academic Article GET IT
Times cited: 56
Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2005 Academic Article GET IT
Times cited: 208
Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2005 Academic Article GET IT
Times cited: 10
Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2005 Academic Article GET IT
Times cited: 58
Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone marrow transplantation. 2005 Information Resource GET IT
Times cited: 32
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2005 Information Resource GET IT
Times cited: 300
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. British journal of haematology. 2005 Academic Article GET IT
Times cited: 142
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 82
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone marrow transplantation. 2005 Academic Article GET IT
Times cited: 55
Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions. Current hematology reports. 2005 Information Resource GET IT
Times cited: 9
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone marrow transplantation. 2005 Academic Article GET IT
Times cited: 104
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 118
Outcome of unrelated transplants in patients with multiple myeloma. Bone marrow transplantation. 2005 Academic Article GET IT
Times cited: 20
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2005 Academic Article GET IT
Times cited: 95
Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?. Hematology. American Society of Hematology. Education Program. 2005 Academic Article GET IT
Times cited: 34
Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2004 Article GET IT
Times cited: 32
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone marrow transplantation. 2004 Academic Article GET IT
Times cited: 173
Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone marrow transplantation. 2004 Academic Article GET IT
Times cited: 45
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone marrow transplantation. 2004 Academic Article GET IT
Times cited: 36
CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone marrow transplantation. 2004 Academic Article GET IT
Times cited: 39
Stem cell transplantation for multiple myeloma: current status and future directions. Current hematology reports. 2004 Information Resource GET IT
Times cited: 8
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004 Academic Article GET IT
Times cited: 49
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 96
Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematology/oncology clinics of North America. 2004 Information Resource GET IT
Times cited: 6
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2004 Academic Article GET IT
Times cited: 10
Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. British journal of haematology. 2004 Academic Article GET IT
Times cited: 76
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone marrow transplantation. 2004 Academic Article GET IT
Times cited: 61
Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions. Current hematology reports. 2004 Information Resource GET IT
Times cited: 5
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone marrow transplantation. 2004 Academic Article GET IT
Times cited: 36
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Academic Article GET IT
Times cited: 319
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Academic Article GET IT
Times cited: 344
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Academic Article GET IT
Times cited: 223
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leukemia & lymphoma. 2004 Academic Article GET IT
Times cited: 19
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2004 Academic Article GET IT
Times cited: 161
Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone marrow transplantation. 2004 Academic Article GET IT
Times cited: 17
Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2004 Academic Article GET IT
Times cited: 45
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood. 2004 Academic Article GET IT
Times cited: 89
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Experimental hematology. 2004 Academic Article GET IT
Times cited: 114
Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia. 2003 Article GET IT
Times cited: 5
Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma. European journal of haematology. 2003 Academic Article GET IT
Times cited: 12
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003 Academic Article GET IT
Times cited: 140
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003 Academic Article GET IT
Times cited: 148
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. British journal of haematology. 2003 Academic Article GET IT
Times cited: 130
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood. 2003 Academic Article GET IT
Times cited: 99
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica. 2003 Academic Article GET IT
Times cited: 97
Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions. Seminars in oncology. 2003 Information Resource GET IT
Times cited: 15
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in oncology. 2003 Conference Paper GET IT
Times cited: 85
Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone marrow transplantation. 2003 Academic Article GET IT
Times cited: 116
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Academic Article GET IT
Times cited: 38
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park, N.Y.). 2003 Information Resource GET IT
Times cited: 32
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. British journal of haematology. 2002 Academic Article GET IT
Times cited: 84
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. British journal of haematology. 2002 Academic Article GET IT
Times cited: 73
Critical review on non-myeloablative stem cell transplantation (NST). Critical reviews in oncology/hematology. 2002 Information Resource GET IT
Times cited: 12
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone marrow transplantation. 2002 Academic Article GET IT
Times cited: 125
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002 Academic Article GET IT
Times cited: 148
Update on non-myeloablative stem cell transplantation for hematologic malignancies. International journal of hematology. 2002 Information Resource GET IT
Times cited: 2
Update on non-myeloablative stem cell transplantation for hematologic malignancies. International journal of hematology. 2002 Information Resource GET IT
Times cited: 9
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002 Academic Article GET IT
Times cited: 407
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Academic Article GET IT
Times cited: 50
Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 89
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Academic Article GET IT
Times cited: 58
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 218
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2002 Academic Article GET IT
Times cited: 46
Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy. Cancer treatment and research. 2002 Information Resource GET IT
Times cited: 6
Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2002 Academic Article GET IT
Times cited: 14
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Academic Article GET IT
Times cited: 320
The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood. 2001 Academic Article GET IT
Times cited: 24
Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer. 2001 Academic Article GET IT
Times cited: 48
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Academic Article GET IT
Times cited: 169
Impact of high-dose chemotherapy on peripheral T-cell lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 136
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. American journal of hematology. 2001 Academic Article GET IT
Times cited: 20
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone marrow transplantation. 2001 Academic Article GET IT
Times cited: 40
High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone marrow transplantation. 2001 Academic Article GET IT
Times cited: 49
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone marrow transplantation. 2001 Academic Article GET IT
Times cited: 126
Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone marrow transplantation. 2001 Academic Article GET IT
Times cited: 77
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone marrow transplantation. 2001 Academic Article GET IT
Times cited: 29
Adenovirus infections in adult recipients of blood and marrow transplants. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001 Academic Article GET IT
Times cited: 243
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Academic Article GET IT
Times cited: 524
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone marrow transplantation. 2001 Academic Article GET IT
Times cited: 11
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 179
Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. Journal of clinical apheresis. 2001 Academic Article GET IT
Times cited: 9
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2001 Academic Article GET IT
Times cited: 55
Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Current opinion in oncology. 2000 Information Resource GET IT
Times cited: 64
Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British journal of haematology. 2000 Information Resource GET IT
Times cited: 185
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone marrow transplantation. 2000 Academic Article GET IT
Times cited: 73
High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone marrow transplantation. 2000 Academic Article GET IT
Times cited: 8
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone marrow transplantation. 2000 Academic Article GET IT
Times cited: 8
Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone marrow transplantation. 2000 Academic Article GET IT
Times cited: 35
Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Outcome of bone marrow transplantation patients requiring mechanical ventilation. Critical care medicine. 2000 Academic Article GET IT
Times cited: 128
Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone marrow transplantation. 2000 Academic Article GET IT
Times cited: 149
Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens. Current oncology reports. 2000 Information Resource GET IT
Times cited: 4
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000 Academic Article GET IT
Times cited: 156
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. Journal of the National Cancer Institute. 2000 Academic Article GET IT
Times cited: 162
Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood. 2000 Academic Article GET IT
Times cited: 28
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. Hematology. American Society of Hematology. Education Program. 2000 Academic Article GET IT
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 178
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000 Academic Article GET IT
Times cited: 232
Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2000 Academic Article GET IT
Times cited: 19
Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Annals of oncology : official journal of the European Society for Medical Oncology. 1999 Academic Article GET IT
Times cited: 109
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leukemia & lymphoma. 1999 Academic Article GET IT
Times cited: 16
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone marrow transplantation. 1999 Academic Article GET IT
Times cited: 59
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Academic Article GET IT
Times cited: 189
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999 Academic Article GET IT
Times cited: 99
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 1999 Academic Article GET IT
Times cited: 44
Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Williston Park, N.Y.). 1999 Academic Article GET IT
Times cited: 60
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone marrow transplantation. 1999 Academic Article GET IT
Times cited: 20
Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1999 Academic Article GET IT
Times cited: 109
Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Current opinion in oncology. 1999 Information Resource GET IT
Times cited: 63
Non myeloablative "mini transplants". Cancer treatment and research. 1999 Information Resource GET IT
Times cited: 32
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 120
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 838
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997 Academic Article GET IT
Times cited: 103
Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. British journal of haematology. 1997 Academic Article GET IT
Times cited: 6
Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone marrow transplantation. 1997 Academic Article GET IT
Times cited: 19
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 1997 Academic Article GET IT
Times cited: 21
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Academic Article GET IT
Times cited: 1044
The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 1997 Academic Article GET IT
Times cited: 30
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. British journal of haematology. 1997 Academic Article GET IT
Times cited: 91
Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leukemia & lymphoma. 1997 Academic Article GET IT
Times cited: 14
Collection of peripheral blood stem cells from normal donors 60 years of age or older. British journal of haematology. 1997 Academic Article GET IT
Times cited: 35
Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone marrow transplantation. 1997 Academic Article GET IT
Times cited: 80
Decitabine studies in chronic and acute myelogenous leukemia. Leukemia. 1997 Academic Article GET IT
Times cited: 46
Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia. 1997 Academic Article GET IT
Times cited: 20
Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone marrow transplantation. 1997 Academic Article GET IT
Times cited: 63
Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone marrow transplantation. 1996 Academic Article GET IT
Times cited: 19
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996 Academic Article GET IT
Times cited: 113
Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone marrow transplantation. 1996 Academic Article GET IT
Times cited: 30
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. The American journal of medicine. 1996 Academic Article GET IT
Times cited: 102
Autologous bone marrow transplantation for leukemia and lymphoma. Cancer treatment and research. 1996 Review GET IT
Times cited: 2
Treatment of relapse after allogeneic bone marrow transplantation. Cancer treatment and research. 1996 Review GET IT
Times cited: 3
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Academic Article GET IT
Times cited: 294
Treatment of chronic myelogenous leukemia. Seminars in oncology. 1995 Information Resource GET IT
Times cited: 21
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines and molecular therapy. 1995 Academic Article GET IT
Times cited: 10
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 1995 Academic Article GET IT
Times cited: 52
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leukemia & lymphoma. 1995 Academic Article GET IT
Times cited: 28
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 106
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone marrow transplantation. 1995 Academic Article GET IT
Times cited: 57
The natural history of chronic myelogenous leukemia in the interferon era. Seminars in hematology. 1995 Information Resource GET IT
Times cited: 19
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Academic Article GET IT
Times cited: 561
Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994 Information Resource GET IT
Times cited: 151
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone marrow transplantation. 1994 Academic Article GET IT
Times cited: 40
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 45
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone marrow transplantation. 1994 Academic Article GET IT
Times cited: 18
Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. The American journal of medicine. 1994 Academic Article GET IT
Times cited: 99
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 172
Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone marrow transplantation. 1994 Academic Article GET IT
Times cited: 40
Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1993 Academic Article GET IT
Times cited: 19
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993 Academic Article GET IT
Times cited: 118
Adverse effects of molgramostim in marrow transplant recipients. Clinical pharmacy. 1993 Academic Article GET IT
Times cited: 5
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 63
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. Bone marrow transplantation. 1993 Academic Article GET IT
Times cited: 15
Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia. Progress in clinical and biological research. 1992 Academic Article GET IT
Times cited: 28

more ...

less ...

Background

education and training

M.D., Central University of Venezuela, School of Medicine (Venezuela) 1985

Contact

full name

Sergio Giralt

VIVO Weill Cornell Medical College

Sergio Giralt Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name